One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies
Open Access
- 27 August 2021
- journal article
- research article
- Published by BMJ in BMJ Open Respiratory Research
- Vol. 8 (1) , e000819
Abstract
Background: Despite currently available standard-of-care inhaled corticosteroid (ICS)/long-acting β2-agonist therapies, a substantial proportion of patients with asthma remain inadequately controlled. This pooled analysis evaluated efficacy and safety of mometasone furoate/indacaterol acetate (MF/IND) versus fluticasone propionate/salmeterol xinafoate (FLU/SAL) in patients with inadequately controlled asthma. Methods: This analysis included patients from PALLADIUM (NCT02554786) and IRIDIUM (NCT02571777) studies who received high-dose MF/IND (320/150 µg) or medium-dose MF/IND (160/150 µg) one time a day or high-dose FLU/SAL (500/50 µg) two times a day for 52 weeks. Reduction in asthma exacerbations, improvement in lung function, asthma control, and safety were evaluated for 52 weeks. Results: In total, 3154 patients (high-dose MF/IND, n=1054; medium-dose MF/IND, n=1044; high-dose FLU/SAL, n=1056) were included. High-dose MF/IND showed 26%, 22% and 19% reductions in rate of severe, moderate or severe, and all (mild, moderate and severe) exacerbations versus high-dose FLU/SAL, respectively, over 52 weeks (all, p1 versus high-dose FLU/SAL at weeks 26 (Δ, 43 mL, p=0.001) and 52 (Δ, 51 mL, p1 with medium-dose MF/IND were comparable with high-dose FLU/SAL over 52 weeks. All treatments improved Asthma Control Questionnaire-7 score from baseline to 52 weeks with no difference between treatments. Safety was comparable between high-dose MF/IND and high-dose FLU/SAL. Conclusions: One time a day, single-inhaler, high-dose MF/IND reduced asthma exacerbations and improved lung function versus two times a day, high-dose FLU/SAL in patients with inadequately controlled asthma. Similarly, improved outcomes were seen with one time a day, medium-dose MF/IND and two times a day, high-dose FLU/SAL, but at a lower ICS dose.Keywords
Funding Information
- Novartis Pharma (Not applicable)
This publication has 22 references indexed in Scilit:
- Asthma Exacerbation Rates in Adults Are Unchanged Over a 5-Year Period Despite High-Intensity TherapyThe Journal of Allergy and Clinical Immunology: In Practice, 2014
- The efficacy of once-daily fluticasone furoate/vilanterol in asthma is comparable with morning or evening dosingRespiratory Medicine, 2013
- The Asthma Control Test and Asthma Control Questionnaire for assessing asthma control: Systematic review and meta-analysisJournal of Allergy and Clinical Immunology, 2013
- Efficacy and onset of action of mometasone furoate/formoterol and fluticasone propionate/salmeterol combination treatment in subjects with persistent asthmaAllergy, Asthma & Clinical Immunology, 2011
- Treatment Comparison of Budesonide/Formoterol with Salmeterol/Fluticasone Propionate in Adults Aged ≥16 Years with AsthmaClinical Drug Investigation, 2010
- Salmeterol/Fluticasone PropionateDrugs, 2009
- Lung function and asthma control with beclomethasone and formoterol in a single inhalerRespiratory Medicine, 2009
- Beclomethasone/formoterol vs fluticasone/salmeterol inhaled combination in moderate to severe asthmaAllergy, 2007
- Identifying ‘well-controlled’ and ‘not well-controlled’ asthma using the Asthma Control QuestionnaireRespiratory Medicine, 2006
- Development and validation of a questionnaire to measure asthma controlEuropean Respiratory Journal, 1999